- Home
- AHCO vs DAWN Comparison
AHCO vs DAWN Comparison
Compare AHCO & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHCO
- DAWN
- Stock Information
- Founded
- AHCO N/A
- DAWN 2018
- Country
- AHCO United States
- DAWN United States
- Employees
- AHCO N/A
- DAWN N/A
- Industry
- AHCO Medical/Nursing Services
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- AHCO Health Care
- DAWN Health Care
- Exchange
- AHCO Nasdaq
- DAWN Nasdaq
- Market Cap
- AHCO 1.3B
- DAWN 1.3B
- IPO Year
- AHCO N/A
- DAWN 2021
- Fundamental
- Price
- AHCO $10.26
- DAWN $12.79
- Analyst Decision
- AHCO Strong Buy
- DAWN Strong Buy
- Analyst Count
- AHCO 5
- DAWN 7
- Target Price
- AHCO $12.40
- DAWN $36.17
- AVG Volume (30 Days)
- AHCO 1.6M
- DAWN 1.0M
- Earning Date
- AHCO 11-05-2024
- DAWN 10-30-2024
- Dividend Yield
- AHCO N/A
- DAWN N/A
- EPS Growth
- AHCO N/A
- DAWN N/A
- EPS
- AHCO N/A
- DAWN N/A
- Revenue
- AHCO $3,262,564,000.00
- DAWN $101,953,000.00
- Revenue This Year
- AHCO $3.06
- DAWN N/A
- Revenue Next Year
- AHCO $2.91
- DAWN $36.10
- P/E Ratio
- AHCO N/A
- DAWN N/A
- Revenue Growth
- AHCO 4.49
- DAWN N/A
- 52 Week Low
- AHCO $6.46
- DAWN $11.94
- 52 Week High
- AHCO $11.90
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- AHCO 48.65
- DAWN 39.97
- Support Level
- AHCO $9.41
- DAWN $12.26
- Resistance Level
- AHCO $10.33
- DAWN $12.81
- Average True Range (ATR)
- AHCO 0.50
- DAWN 0.52
- MACD
- AHCO 0.04
- DAWN -0.05
- Stochastic Oscillator
- AHCO 55.65
- DAWN 28.94
About AHCO AdaptHealth Corp.
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.